A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab- and Talquetamab-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Teclistamab (Primary) ; Immunoglobulins
Indications Multiple myeloma
Focus Adverse reactions
Acronyms GMMG-HD10/DSMM XX; MajesTEC-5

08 Dec 2024 Results presented in the Johnson & Johnson Media Release.
08 Dec 2024 According to a Johnson & Johnson media release, result data from this study were presented in an oral presentations at the 2024 American Society of Hematology (ASH) Annual Meeting.
19 Nov 2024 According to a Johnson & Johnson media release, results from this study will be presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego from December 7-10.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com